Effects of Endocannabinoid System Modulation on Cholinergic-Induced Anxiety-like Behaviors in Mice.
- 1Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4a Chodzki Str., 20-093 Lublin, Poland.
- 2Experimental Medicine Center (OMD), Medical University of Lublin, Jaczewskiego 8D, 20-090 Lublin, Poland.
- 3Department of Medical Informatics and Statistics with E-Health Lab, Medical University of Lublin, Jaczewskiego 4 Street, 20-954 Lublin, Poland.
Abstract
Background: Anxiety disorders are clinically significant non-cognitive symptoms of many neuropsychiatric disorders, often accompanying progressive memory deficits and reflecting neurochemical dysregulation, particularly cholinergic dysfunction. Current therapy for these disorders is focused on the memory deficits but does not improve emotional symptoms and may even worsen anxiety. Therefore, novel therapeutic strategies are needed that address both cognitive and non-cognitive symptoms. Aim: Recent studies suggest that the endocannabinoid system (ECS) may play a key role in regulating cognitive and emotional processes, including anxiety. The aim of the study was to evaluate how direct (via selective ligands of cannabinoid CB1 and CB2 receptors) and indirect (via inhibitors of endocannabinoid-degrading enzymes-fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)) modulation of ECS activity affects anxiety-like behaviors induced by pharmacological modification of cholinergic neurotransmission (by using nicotine or scopolamine). Methods: Anxiety-related behaviors were assessed in mice using the elevated plus maze (EPM) test. Results: CB1 receptor agonist oleamide (5 mg/kg), FAAH inhibitor URB 597 (0.1 mg/kg), and MAGL inhibitor JZL 184 (20 mg/kg) attenuated the anxiogenic effects of nicotine (0.1 mg/kg). Additionally, oleamide (5 mg/kg), CB1/CB2 receptor agonist WIN 55,212-2 (0.25 mg/kg), CB2 receptor antagonist AM 630 (0.25 mg/kg), and JZL 184 (20 mg/kg) attenuated the anxiogenic effects induced by scopolamine (1 mg/kg). Conclusions: Both direct and indirect ECS modulation demonstrated an impact on anxiety-like responses induced by cholinergic ligands. This potential relationship between ECS and cholinergic pathways provides additional insights into anxiety regulation and may represent a promising starting point for further research into targeted anxiolytic mechanisms in the central nervous system (CNS).
Related
- Vitamin B1 administration attenuates anxiety and depression-like behaviors induced by nicotine abstinence in chronically stressed rats
- Host response against SARS-CoV-2 infection is impacted by allosteric modulation of cholinergic and purinergic receptors
- The Neuroprotective Properties of Shogaol-Enriched Ginger Extract (SEGE) Mitigate Synaptic, Cholinergic, and Metabolic Brain Dysfunction in a Mouse Model of Metals and High-Fat-Diet-Induced Neuropathology
- Music performance anxiety and restrictive dietary behaviors: a moderated serial mediation model
- MCH-02, a synthetic macamide analog with in vitro FAAH-inhibitory activity, modulates hippocampal endocannabinoid system and BK channel expression without preventing PTZ-induced progressive seizure susceptibility in rats
BibTeX
@article{krukslomka2026effects,
title = {{Effects of Endocannabinoid System Modulation on Cholinergic-Induced Anxiety-like Behaviors in Mice.}},
author = {Marta Kruk-Slomka and Tomasz Slomka and Agnieszka Dzik and Grazyna Biala},
journal = {Pharmaceuticals (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/ph19101574},
url = {https://europepmc.org/article/MED/42943271},
note = {CC BY},
}
RIS
TY - JOUR
TI - Effects of Endocannabinoid System Modulation on Cholinergic-Induced Anxiety-like Behaviors in Mice.
AU - Marta Kruk-Slomka
AU - Tomasz Slomka
AU - Agnieszka Dzik
AU - Grazyna Biala
PY - 2026
DA - 2026/10/04
JO - Pharmaceuticals (Basel, Switzerland)
DO - 10.3390/ph19101574
UR - https://europepmc.org/article/MED/42943271
AB - Background: Anxiety disorders are clinically significant non-cognitive symptoms of many neuropsychiatric disorders, often accompanying progressive memory deficits and reflecting neurochemical dysregulation, particularly cholinergic dysfunction. Current therapy for these disorders is focused on the memory deficits but does not improve emotional symptoms and may even worsen anxiety. Therefore, novel therapeutic strategies are needed that address both cognitive and non-cognitive symptoms. Aim: Recent studies suggest that the endocannabinoid system (ECS) may play a key role in regulating cognitive and emotional processes, including anxiety. The aim of the study was to evaluate how direct (via selective ligands of cannabinoid CB1 and CB2 receptors) and indirect (via inhibitors of endocannabinoid-degrading enzymes-fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)) modulation of ECS activity affects anxiety-like behaviors induced by pharmacological modification of cholinergic neurotransmission (by using nicotine or scopolamine). Methods: Anxiety-related behaviors were assessed in mice using the elevated plus maze (EPM) test. Results: CB1 receptor agonist oleamide (5 mg/kg), FAAH inhibitor URB 597 (0.1 mg/kg), and MAGL inhibitor JZL 184 (20 mg/kg) attenuated the anxiogenic effects of nicotine (0.1 mg/kg). Additionally, oleamide (5 mg/kg), CB1/CB2 receptor agonist WIN 55,212-2 (0.25 mg/kg), CB2 receptor antagonist AM 630 (0.25 mg/kg), and JZL 184 (20 mg/kg) attenuated the anxiogenic effects induced by scopolamine (1 mg/kg). Conclusions: Both direct and indirect ECS modulation demonstrated an impact on anxiety-like responses induced by cholinergic ligands. This potential relationship between ECS and cholinergic pathways provides additional insights into anxiety regulation and may represent a promising starting point for further research into targeted anxiolytic mechanisms in the central nervous system (CNS).
SN - 1424-8247
ER -